Literature DB >> 22704721

Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.

J P Hsu1, M C Phoon, Gerald C H Koh, Mark I C Chen, Vernon J Lee, Y Wu, M L Xie, Angela Cheong, Y S Leo, Vincent T K Chow.   

Abstract

BACKGROUND: The recent H1N1 pandemic virus that emerged in 2009 resulted in high morbidity rates mainly in younger individuals, albeit with relatively low mortality. We investigated both humoral and cellular immune responses against the pandemic H1N1 2009 virus before and after immunization with inactivated H1N1 2009 vaccine.
METHODS: We obtained paired blood specimens from a cohort of participants from nursing homes (n=108) and a public hospital (n=60) in Singapore. Serum samples were tested for neutralizing antibodies against H1N1 2009 using microneutralization assays, while peripheral blood mononuclear cells were subjected to interferon-γ enzyme-linked immunosorbent spot (ELISPOT) assays for whole virus-specific T-cell responses.
RESULTS: We observed significant increases in geometric mean titers of neutralizing antibodies after H1N1 2009 vaccination (from 23.6 pre-vaccination to 94.7 post-vaccination). Approximately 77% and 54% of the cohort exhibited ≥2-fold and ≥4-fold increases in neutralizing antibody titers following vaccination; 89.9% of the cohort had a post-vaccination antibody titer of ≥32. Adjusted for gender, participants aged ≥60 years were less likely to have a ≥4-fold increase in antibody titers after vaccination than those aged <60 years (0.48; 95% confidence interval (95% CI) 0.32-0.71, p=0.007). There was a 1.4-fold elevation in H1N1 2009-specific T-cell responses after vaccination (p<0.05). Adjusted for gender, age ≥60 years was positively associated with a greater increase in T-cell response (β=4.9, 95% CI 1.58-8.29, p=0.018). No significant correlation was observed between humoral and cellular immune responses.
CONCLUSIONS: Influenza vaccination elicits significant neutralizing antibody and T-cell responses to pandemic H1N1 2009 influenza virus. However, in response to vaccination, increases in neutralizing antibody titers were comparatively lower but T-cell responses were higher in older participants. Therefore, our study suggests that memory T-cells may play a crucial role in protecting older individuals against pandemic H1N1 2009 infection.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704721     DOI: 10.1016/j.ijid.2012.04.010

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  16 in total

Review 1.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Authors:  Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel
Journal:  Vaccine       Date:  2015-12-04       Impact factor: 3.641

3.  Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.

Authors:  Sinthujan Jegaskanda; Thakshila H Amarasena; Karen L Laurie; Hyon-Xhi Tan; Jeff Butler; Matthew S Parsons; Sheilajen Alcantara; Janka Petravic; Miles P Davenport; Aeron C Hurt; Patrick C Reading; Stephen J Kent
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

4.  Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly.

Authors:  Heidi Theeten; Catharina Mathei; Kelly Peeters; Benson Ogunjimi; Herman Goossens; Margareta Ieven; Pierre Van Damme; Nathalie Cools
Journal:  Viral Immunol       Date:  2016-03-22       Impact factor: 2.257

5.  Serological response of patients with influenza A (H1N1) pdm09-associated pneumonia: an observational study.

Authors:  Nasikarn Angkasekwinai; Bualan Kaewnapha; Duangdao Waywa; Peerawong Werarak; Sasima Tongsai; Kulkanya Chokephaibulkit; Visanu Thamlikitkul; Sontana Siritantikorn
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

6.  BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection.

Authors:  Ki-Hye Kim; Young-Tae Lee; Yoonsuh Park; Eun-Ju Ko; Yu-Jin Jung; Yu-Jin Kim; Eun-Kyeong Jo; Sang-Moo Kang
Journal:  Biomedicines       Date:  2021-05-05

7.  B cell responses to the 2011/12-influenza vaccine in the aged.

Authors:  Raj K Kurupati; Senthil Kannan; Zhi-Quan Xiang; Susan Doyle; Sarah Ratcliffe; Kenneth E Schmader; Hildegund C J Ertl
Journal:  Aging (Albany NY)       Date:  2013-03       Impact factor: 5.682

8.  Influenza mortality in the United States, 2009 pandemic: burden, timing and age distribution.

Authors:  Ann M Nguyen; Andrew Noymer
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in England.

Authors:  Chee-Fu Yung; Nick Andrews; Katja Hoschler; Elizabeth Miller
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

10.  Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.

Authors:  Robert B Couch; José M Bayas; Covadonga Caso; Innocent Nnadi Mbawuike; Concepción Núñez López; Carine Claeys; Mohamed El Idrissi; Caroline Hervé; Béatrice Laupèze; Lidia Oostvogels; Philippe Moris
Journal:  BMC Infect Dis       Date:  2014-07-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.